British techbio startup Qureight has secured $8.5 million in an oversubscribed Series A round. Launched in 2018, Qureight wants to simplify how pharma companies deal with the complex datasets often used during clinical trials. "For example, we can start to structure images of lungs using AI," said cofounder and CEO Muhunthan Thillai. The startup primarily works with pharmaceutical companies, including heavyweights such as AstraZeneca, as well as hospitals and clinical research organizations. Check out the 11-slide pitch deck used to secure the fresh funding.

---

Persons: Qureight, Muhunthan Thillai, Thillai, Hargreave Hale Organizations: pharma, Business, AstraZeneca, Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Playfair, Fund, Cambridge Angels Locations: Cambridge, Meltwind